Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 6/20 | 0.58 |
| ▸ | ADH1A | P07327 | 6/20 | 0.58 |
| ▸ | ADH7 | P40394 | 5/20 | 0.58 |
| ▸ | ADH1C | P00326 | 5/20 | 0.58 |
| ▸ | ADH4 | P08319 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302803 | 0.98 | ADH1B (0.61) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL5646910 | 0.98 | ADH1B (0.61) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL3020274 | 0.95 | — | — | |
| SCHEMBL1899269 | 0.90 | — | — | |
| SCHEMBL3024930 | 0.86 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL22104300 | 0.86 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL303075 | 0.85 | ADH1B (0.57) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL304406 | 0.85 | ADH1B (0.57) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL8952319 | 0.83 | SIGMAR1 (0.60) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL8861073 | 0.83 | SIGMAR1 (0.60) | ADH1BADH1AADH7ADH1CADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008127727-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-4585774-A | Aniline derivatives and cardiotonic composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| EP-0064878-B1 | NOVEL ANILINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CARDIOTONIC COMPOSITIONS CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-07-24 | — | — | EP | disclosed |
| EP-0064878-A1 | Novel aniline derivatives, process for preparing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1982-11-17 | — | — | EP | disclosed |
| US-4064135-A | Certain thiazole-5-carboxamide compounds | SYNTEX (U.S.A.) INC. (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | ADH1B 2746/4885ADH1A 2285/4885ADH7 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.